Ponentes y moderadores
Jordi Bruix, MD, PhD
Barcelona Clinic Liver Cancer Group
Liver Unit at the Hospital Clínic of Barcelona
University of Barcelona. IDIBAPS. Barcelona, Spain
Jordi Bruix is Professor of Medicine at the University of Barcelona and Director of the Barcelona Clinic Liver Cancer Group.
He has been principal investigator of studies and clinical trials that have changed practice in the field of HCC, this including development of diagnostic criteria and prognostic models, and establishing chemoembolization, sorafenib and regorafenib as conventional therapy. He has developed and sequentially updated the BCLC staging and treatment strategy that has been endorsed by several international scientific associations to guide management of patients with HCC. He has authored more than 300 peer reviewed manuscripts and Evidence-based Practice Guidelines for Hepatocellular Carcinoma at EASL, AASLD and WGO.
Dr. Bruix is a member of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). He founded the International Liver Cancer Association (ILCA) and was nominated President from 2006 to 2009. His task has primed major recognitions such as the Hans Popper Award, the Golden Medal Award from the Canadian Association for the Study of the Liver, the EASL Recognition Award and the AASLD Distinguished Achievement Award.
He has been Associate Editor of Journal of Hepatology, Liver Transplantation and Hepatology, and is currently Co-Editor in Chief of Seminars in Liver Disease.